Bimergen Energy's subsidiary, Emergen Commodities, has applied for a retail electric provider certificate in Texas to supply electricity directly to large data centers. This move aims to tap into Texas' $200 billion data center market, creating recurring revenue through long-term supply agreements. The application is under review by the Public Utility Commission of Texas, and if approved, it will expand Bimergen's role from battery storage to retail electricity supply. The company is also securing credit support to serve these high-demand customers, aligning with its broader strategy to grow in the energy market.
Bimergen Energy's retail electricity initiative targets Texas' $200 billion data center development pipeline. For readers following the energy sector, here is Pluang's market snapshot as of Oct 26, 2026 16:11 WIB: out of 79 priced US energy stocks, 14 rose and 51 fell. Notable movers include VG at USD 13.78 with a 1-day change of -1.57% and a typical hold time of 5 days, OXY at USD 63.26 down 1.42% with a 93-day hold, and APA at USD 51.17 down 1.41% with an 8-day hold.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
